TY - JOUR T1 - On the survival of individuals diagnosed with type 2 diabetes mellitus in the United Kingdom: a retrospective matched cohort study JF - medRxiv DO - 10.1101/2021.12.13.21267749 SP - 2021.12.13.21267749 AU - Njabulo Ncube AU - Elena Kulinskaya AU - Nicholas Steel AU - Dmitry Pchejetski Y1 - 2021/01/01 UR - http://medrxiv.org/content/early/2021/12/16/2021.12.13.21267749.abstract N2 - Objective To estimate long-term hazards of all-cause mortality following a diagnosis of type 2 diabetes mellitus (T2DM) using electronic primary care data.Methodology Retrospective matched cohort study using electronic health records from THIN primary care database. The study included individuals born between 1930 and 1960, diagnosed with T2DM between 2000 and 2016 and aged 50-74 years and excluded those with pre-existing stroke, cancer, cognitive impairment, lower limb amputation or chronic kidney disease (CKD) stages 3 to 5. T2DM individuals were matched at diagnosis to at most 3 controls by age, gender and general practice (GP) and followed up to 1 January 2017. Time-varying hazards of all-cause mortality were then estimated using Gompertz-double-Cox model with frailty on GP, adjusting for medical history, socio-demographic and lifestyle factors.Results A total of 221 182 (57.6% Males, 30.8% T2DM) individuals were selected for the study of whom 29 618 (13.4%) died during follow-up. The adjusted mortality hazard of type 2 diabetes mellitus (T2DM) was estimated to be 1.21[1.12-1.3] and 1.52[1.44-1.6] among individuals diagnosed at 50-59 years and 60-74 years, respectively, compared to controls. Deprivation, obesity, smoking and comorbidities affected survival of cases and controls equally. Compared to the 1930-39 birth cohort, all-cause mortality hazards were reduced in the 1940-49 cohort, but increased at older ages in the 1950-60 birth cohort for both cases and controls.Conclusion T2DM is associated with raised all-cause mortality hazards which increase with age of diagnosis. These hazards associated with age at diagnosis are constant across all birth cohorts demonstrating a lack of progress over time in reducing the relative risks of all-cause mortality associated with T2DM. A further study that includes people born after 1960 is needed to fully understand the emerging higher mortality hazards among the younger birth cohorts.What is already known about this study?- Diagnosis of type 2 diabetes mellitus (T2DM) is associated with increased all-cause mortality risk.What are the new findings?- The increased all-cause mortality associated with T2DM was lower than previously reported.- The all-cause mortality risk associated with T2DM increased with increasing age at diagnosis.- The all-cause mortality risk associated with T2DM remained constant across all birth cohorts.- The all-cause mortality risk is increased at later ages among the younger birth cohorts in individuals with and without T2DM.How might these results change the focus of research or clinical practice?- Further research is needed on individuals born after 1960 to explore the increased all-cause mortality hazards in recent birth cohorts.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThe study was funded by The Institute and Faculty of Actuaries.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This study was approved by THIN Scientific Review Committee (SRC) with approval number 16THIN095.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors. ER -